Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Vaccinating goats with live wildtype Mccp strain ILRI181 induces protective immunity against CCPP

38 views

Published on

Presented by Elise Schieck at the European Mycoplasma Conference, London, 18-19 March 2019

Published in: Science
  • Be the first to comment

  • Be the first to like this

Vaccinating goats with live wildtype Mccp strain ILRI181 induces protective immunity against CCPP

  1. 1. Vaccinating goats with live wildtype Mccp strain ILRI181 induces protective immunity against CCPP Elise Schieck European Mycoplasma Conference, London, 18-19 March 2019
  2. 2. Background Is the challenge model too harsh? Is there a future for Mccp live vaccines? Test the challenge model against the saponized bacterine vaccine Test whether the wild type ILRI181 can induce a protective immune response after subcutaneous immunisation
  3. 3. Trial design Entry ABSL2 Vaccination Challenge End of Trial, Necropsies Days post vaccination -14 0 29 50
  4. 4. Trial design Vaccinations, subcutaneous: T1 (live wild-type ILRI181) T2 (inactivated ILRI181) T3 (inactivated Abomsa (CIRAD)) T4 (control, PBS) • Body temperature >40.5 C for >3days • Body weight loss >10% in 7 days • Breathing frequency >50/min for >3days • Signs of moderate to severe pain Eight goats per group, randomised, blinded: Monitoring and sampling: Daily: Rectal temperature, heart rate, breathing rate. Three times weekly: weight. Sampling, serum: twice weekly End-point criteria:
  5. 5. Challenge with live wild-type Mccp ILRI181 Liljander et al. 2019 0 1 4 Intranasal 108 CCU Transtracheal 108 CCU Days post challenge 29 30 33 Days post vaccination
  6. 6. Results - survival Log-rank test: T1 vs T4: p=0.0001 T2 vs T4: p=0.0001 T3 vs T4: p=0.0014 T1: Live ILRI181 T2: Inactivated ILRI181 T3: Inactivated Abomsa T4: PBS 0 5 10 15 20 25 30 35 40 45 50 55 0 50 100 Days post vaccination Percentsurvival ChallengeVaccination
  7. 7. Results – Clinical monitoring T1: Live ILRI181 T2: Inactivated ILRI181 T3: Inactivated Abomsa T4: PBS -15 -10 -5 0 5 10 15 20 25 30 35 40 45 50 38 39 40 41 42 Days post vaccination Temperature(°C) ChallengeVaccination
  8. 8. Results – Clinical monitoring -15 -10 -5 0 5 10 15 20 25 30 35 40 45 50 38 39 40 41 42 Days post vaccination Temperature(°C) ChallengeVaccination -15 -10 -5 0 5 10 15 20 25 30 35 40 45 50 10 20 30 40 50 60 Days post vaccination Breathingrate(perminute) ChallengeVaccination -15 -10 -5 0 5 10 15 20 25 30 35 40 45 50 60 70 80 90 100 110 120 130 140 Days post vaccination Heartrate(beatsperminute) T1: Live ILRI181 T2: Inactivated ILRI181 T3: Inactivated Abomsa T4: PBS ChallengeVaccination -15 -10 -5 0 5 10 15 20 25 30 35 40 45 50 25 30 35 40 45 Days post vaccination bodyweight(kg) ChallengeVaccination A B C D A: Body temperature B: Heart rate C: Breathing frequency D: Body weight
  9. 9. Results – Necropsy Schematic subdivision of lungs into triangle sections for pneumonia and pleuritis scoring purposes
  10. 10. Results – Pathology results Group Vaccine Animal ID Day of euthanasia (days post challenge) Pneumonia Pleural fluid collected (ml) Lung consolidation score Pleuritis score Fever ≥40,5 °C Fever <40,5°C Coughing several times after challenge T1 Live ILRI181 CM259 15 yes 320 16,9 16,9 yes yes yes CP006 21 no 0 0 0 no no no CP012 21 no 0 0 0 no yes yes CP015 22 no 0 0 0 no no no CP017 22 no 0 0 0 no no no CP018 22 no 0 0 0 no no no CP029 23 no 0 0 0 no no no CP030 23 no 0 0 0 no no no T2 Inactivated ILRI181 CM262 21 no 0 0 0,7 no no yes CP008 21 no 0 0 0 no no no CP016 21 no 0 0 0 no no yes CP026 21 no 0 0 5,9 no no yes CP001 22 no 0 0 0 no no no CP020 22 no 0 0 0 no no no CP022 22 no 0 0 0 no no yes T3 Inactivated Abomsa (CIRAD) CP005 13 yes 75 18,6 18,6 yes yes yes CP004 14 yes 115 16,2 14,8 yes yes yes CP028 15 yes 22 7,1 7,1 yes no yes CP002 21 no 0 0 0 no yes no CP013 22 no 0 0 1,5 no no no CP021 22 no 0 0 0 no no no CP023 23 no 0 0 0 no no no CP025 23 no 0 0 0 no no no T4 PBS CP009 11 yes 70 16,3 16,3 yes no yes CP003 12 yes 135 16,6 16,6 yes no yes CP011 12 yes 45 15 14,3 yes no yes CP014 12 yes 135 13,1 12,1 yes yes yes CP019 13 yes 20 15,5 15,5 yes no yes CP024 13 yes 150 20,1 20,1 yes yes yes CP027 13 yes 295 17,1 17,1 yes yes yes CP007 15 yes 75 16,2 15,5 yes yes yes † † †
  11. 11. Results - Protection Vaccination group Proportion (euthanized/total) Proportion (euthanized/total) In control group T4 χ 2 test Vaccine Efficacy =Protection against severe disease/mortality T1 (live ILRI181) 1/8 8/8 p<0.001 87.5% T2 (inactivated ILRI181) 0/7 8/8 p<0.001 100% T3 (inactivated Abomsa) 3/8 8/8 p=0.009 62.5%
  12. 12. Results - Protection Vaccination group Proportion (clinical signs/total) Proportion (clinical signs/total) in control group T4 χ 2 test Vaccine Efficacy =Protection against clinical signs: fever or lesions T1 (live ILRI181) 2/8 8/8 p=0.003 75% T2 (inactivated ILRI181) 2/7 8/8 p=0.005 71.4% T3 (inactivated Abomsa) 5/8 8/8 p=0.063 62.5%
  13. 13. Conclusion Is the challenge model too harsh? Is there a future for Mccp live vaccines?
  14. 14. Conclusion Is the challenge model too harsh? -Test the challenge model against the saponized bacterine vaccine -No it’s not! The challenge model will be very useful for testing novel vaccines Is there a future for Mccp live vaccines? -Test whether the wild type ILRI181 can induce a protective immune response after subcutaneous immunization -Yes there is! The next challenge will be to get the right level of attenuation
  15. 15. Thank you! Flavio Patrice Odhiambo Lameck Giuseppe Gesharisha Marren Joerg Jores and Anne Liljander Francois Thiaucourt and Lucia Manso-Silvan Vish Nene and Jeremy Salt Cecilia
  16. 16. This presentation is licensed for use under the Creative Commons Attribution 4.0 International Licence. better lives through livestock ilri.org ILRI thanks all donors and organizations which globally support its work through their contributions to the CGIAR Trust Fund

×